罕见基因多态性对日本人群5-氟尿嘧啶治疗的重要性

Importance of Rare Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population.

作者信息

Hishinuma Eiji, Narita Yoko, Obuchi Kai, Ueda Akiko, Saito Sakae, Tadaka Shu, Kinoshita Kengo, Maekawa Masamitsu, Mano Nariyasu, Hirasawa Noriyasu, Hiratsuka Masahiro

机构信息

Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

出版信息

Front Pharmacol. 2022 Jun 15;13:930470. doi: 10.3389/fphar.2022.930470. eCollection 2022.

Abstract

Dihydropyrimidine dehydrogenase (DPD), encoded by the gene, is the rate-limiting enzyme in 5-fluorouracil (5-FU) degradation. In Caucasians, four risk variants are recognized to be responsible for interindividual variations in the development of 5-FU toxicity. However, these risk variants have not been identified in Asian populations. Recently, 41 allelic variants, including 15 novel single nucleotide variants, were identified in 3,554 Japanese individuals by analyzing their whole-genome sequences; however, the effects of these variants on DPD enzymatic activity remain unknown. In the present study, an analysis was performed on 41 DPD allelic variants and three DPD risk variants to elucidate the changes in enzymatic activity. Wild-type and 44 DPD-variant proteins were heterologously expressed in 293FT cells. DPD expression levels and dimerization of DPD were determined by immunoblotting after SDS-PAGE and blue native PAGE, respectively. The enzymatic activity of DPD was evaluated by quantification of dihydro-5-FU, a metabolite of 5-FU, using high-performance liquid chromatography-tandem mass spectrometry. Moreover, we used 3D simulation modeling to analyze the effect of amino acid substitutions on the conformation of DPD. Among the 41 DPD variants, seven exhibited drastically decreased intrinsic clearance ( ) compared to the wild-type protein. Moreover, R353C and G926V exhibited no enzymatic activity, and the band patterns observed in the immunoblots after blue native PAGE indicated that DPD dimerization is required for its enzymatic activity. Our data suggest that these variants may contribute to the significant inter-individual variability observed in the pharmacokinetics and pharmacodynamics of 5-FU. In our study, nine DPD variants exhibited drastically decreased or no enzymatic activity due to dimerization inhibition or conformational changes in each domain. Especially, the rare variants, although at very low frequencies, may serve as important pharmacogenomic markers associated with the severe 5-FU toxicity in Japanese population.

摘要

由该基因编码的二氢嘧啶脱氢酶(DPD)是5-氟尿嘧啶(5-FU)降解的限速酶。在白种人中,四种风险变异被认为是导致5-FU毒性个体差异的原因。然而,这些风险变异在亚洲人群中尚未被鉴定出来。最近,通过分析3554名日本人的全基因组序列,鉴定出41种等位基因变异,包括15种新的单核苷酸变异;然而,这些变异对DPD酶活性的影响仍然未知。在本研究中,对41种DPD等位基因变异和三种DPD风险变异进行了分析,以阐明酶活性的变化。野生型和44种DPD变异蛋白在293FT细胞中异源表达。分别通过SDS-PAGE后的免疫印迹和蓝色非变性PAGE测定DPD的表达水平和二聚化。使用高效液相色谱-串联质谱法通过定量5-FU的代谢产物二氢-5-FU来评估DPD的酶活性。此外,我们使用三维模拟建模来分析氨基酸取代对DPD构象的影响。在41种DPD变异中,有7种与野生型蛋白相比表现出固有清除率( )大幅降低。此外,R353C和G926V没有酶活性,蓝色非变性PAGE后免疫印迹中观察到的条带模式表明DPD二聚化是其酶活性所必需的。我们的数据表明,这些变异可能导致5-FU药代动力学和药效学中观察到的个体间显著差异。在我们的研究中,9种DPD变异由于各结构域的二聚化抑制或构象变化而表现出酶活性大幅降低或无酶活性。特别是,罕见的变异,尽管频率非常低,可能是与日本人群中严重5-FU毒性相关的重要药物基因组学标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c57e/9242541/d477245914bb/fphar-13-930470-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索